SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Miscellaneous >

Therapeutic Solutions International, Inc. (TSOI)

Add TSOI Price Alert      Hide Sticky   Hide Intro
Moderator: centsability4me
Search This Board: 
Last Post: 4/21/2017 7:30:29 PM - Followers: 82 - Board type: Free - Posts Today: 0

A public clinical stage company focused on immune modulation for the treatment of cancer and other specific diseases.

The Company’s corporate website is  New products can be viewed on and ordered at

Recent News:

Therapeutic Solutions International's Subsidiary, Emvolio, Inc., Files Investigational New Drug Application for StemVacs Cancer Immunotherapy

Therapeutic Solutions International Announces Filing of new Immunotherapy Patent and Exclusive Patent License Agreement with Subsidiary Emvolio, Inc.

Therapeutic Solutions Receives Allowance on Patent Claim from the US Patent Office Covering ProJuvenol® Active Ingredient Pterostilbene in Cancer Immunotherapies

Therapeutic Solutions International Reports Augmentation of Cancer Immunotherapy Using Pterostilbene
Share Structure - 46M Float
Shares Outstanding 682,751,000 a/o July 31 , 2016
Float 46,312,028 a/o July 31 , 2016
Authorized Shares 995,000,000 a/o July 31 , 2016


Omnibiome , Inc .
(As of July 20 , 2016 TSI owns approximately 73.75% of the outstanding shares of OmniBiome , Inc .)

Emvolio , Inc .

(As of April 10 , 2017 Emvolio , Inc is majority-owned by TSI)

Nutraceutical Division:

Officers and Directors:

 Timothy G. Dixon – President, CEO, & Chairman
Mr. Dixon currently serves as Chief Executive Officer, President, and Chairman of Therapeutic Solutions International, Inc. Mr. Dixon also serves as President and Chairman of OmniBiome, Inc. Mr. Dixon previously served as the President of TMD Courses, Inc. from 2006 to 2012 and; as the President of Splint Decisions Inc. from 2010 to 2011. Mr. Dixon has attended hundreds of hours of continuing medical/dental education throughout the years and has produced many educational DVD’s used by dental professionals worldwide on the subject of parafunctional control, migraine prevention, therapeutic Botox injections, migraine pathophysiology, dental sleep medicine, and other therapeutic protocols. Mr. Dixon also has extensive experience in dealing with corporate compliance matters with the U.S. Food and Drug Administration, (FDA) as well as many international regulatory bodies.

Gerry B. Berg – Vice President, CFO, Director
Gerry B. Berg has served as our Vice-President and Chief Financial Officer since April 20, 2011.  Mr. Berg became a director of the Company on August 24, 2012.  Mr. Berg has over 30 years of senior management experience working with private and public companies.  From May 2010 to March 2011, Mr. Berg served as President and Chairman of the Board of Directors of Friendly Auto Dealers, Inc., and also served in a consulting capacity from March 2009 to May 2010.
Mr. Berg holds a Bachelors of Science in Accounting from Walsh College where he graduated Cum Laude.  Mr. Berg became a Certified Public Accountant in the State of Michigan in 1979 and in the State of California in 1984.  Mr. Berg does not currently practice as a Certified Public Accountant.

Thomas E. Ichim, Ph.D – Director

Dr. Ichim was appointed to the Board of Directors on January 22, 2016.  Dr. Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies including Batu Biologics, Inc., Medvax Pharma Corp, ToleroTech Inc, bioRASI, and OncoMune LLC. To date he has published 99 peer-reviewed articles and is co-editor of the textbooks “RNA Interference: From Bench to Clinical Translation” and “Immuno-Oncology Text Book.”
Dr. Ichim is an ad-hoc editor and sits on several editorial boards. Dr Ichim is inventor on over 50 patents and patent applications. Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Dr. Ichim has extensive experience in product development, regulatory filings, and business development.
Dr. Ichim has a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada, a MSc in Microbiology and Immunology a University of Western Ontario, London, Ontario, Canada and a Ph.D in Immunology from the University of Sciences Arts and Technology, Olveston Monserrat.

Hong Ma, MD, Ph.D., M.B.A. – Chief Scientific Officer
Dr. Ma has an extensive history in academic and translational research. Subsequent to completing her medical degree, she performed basic research in the area of molecular biology of endothelial-associated pathways in her doctorate and postdoctoral studies. She has been critical in establishing numerous ventures and collaborations in the area of biosciences. Dr. Ma has over 20 peer-reviewed publications and has worked with prestigious institutions in the USA, China, and Japan. She received her M.D. from Dalian Medical University, her Ph.D. in Cardiovascular Pharmacology at Asahikawa Medical College, and has also earned her MBA at the Rady School of Management at the University of California San Diego.

Contact :
CEO email address:  

Therapeutic Solutions International, Inc.
4093 Oceanside Blvd Suite B
Oceanside CA 92056

IR Email:


Disclaimer : All of the information presented in the IBOX , Stickies , or posts of  individual opinions , should not be considered as recommendations to buy , sell , or hold this stock .

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
TSOI News: Current Report Filing (8-k) 04/18/2017 01:56:21 PM
TSOI News: Quarterly Report (10-q) 04/17/2017 03:00:30 PM
TSOI News: Quarterly Report (10-q) 04/13/2017 05:15:59 PM
TSOI News: Therapeutic Solutions International’s Sub, Emvolio, Inc., Files Investigational New Drug Application for StemVacs Cancer 04/12/2017 09:31:16 AM
TSOI News: Therapeutic Solutions International Announces Filing new Immunotherapy Patent and Exclusive Patent License Agreement with Sub 04/10/2017 01:05:28 PM
#5695   StemVacs mentioned by centsability4me 04/21/17 07:30:29 PM
#5694   TSOI Stemvacs mentioned on other sites : centsability4me 04/21/17 06:01:04 PM
#5693   Link to 8K centsability4me 04/19/17 08:17:14 AM
#5692   sold 75% holding a core just in case, harry crumb 04/19/17 12:04:04 AM
#5691   0,016 !!!!!! corvatsch 04/18/17 02:37:42 PM
#5690   Got the Realtime 8KSpy Alert on TSOI $TSOI Zardiw 04/18/17 02:35:14 PM
#5689   another 10Q out centsability4me 04/18/17 07:25:43 AM
#5688   Would be good centsability4me 04/17/17 01:32:23 PM
#5687   10Q filing out centsability4me 04/13/17 09:47:41 PM
#5686   .01 centsability4me 04/13/17 03:08:01 PM
#5685   0,007x0,0084... sell of news ??? corvatsch 04/12/17 01:33:57 PM
#5684   TSOI NEWS 4/12/17 from Marketwired centsability4me 04/12/17 10:00:58 AM
#5683   More on Biorasi Inc centsability4me 04/12/17 09:43:22 AM
#5682   ***TSOI NEWS 4/12/17*** centsability4me 04/12/17 09:37:13 AM
#5681   Low Float, centsability4me 04/11/17 12:32:41 PM
#5680   Stock experiencing dilution? Doesn't make any sense Campeese 04/11/17 12:17:45 PM
#5679   TSOI new subsidiary Emvolio Inc centsability4me 04/10/17 07:08:42 PM
#5678   TSOI**Immunotherapy/Stem Cell Patent News stervc 04/10/17 12:33:18 PM
#5677   0,013....... corvatsch 04/10/17 11:49:11 AM
#5676   TSOI patents : centsability4me 04/08/17 12:07:28 PM
#5675   TSOI Update centsability4me 04/08/17 11:54:45 AM
#5674   0,0055 x 0,0084... corvatsch 04/07/17 01:40:06 PM
#5673   0,011.... corvatsch 04/05/17 12:05:22 PM
#5672   .0064 X .0087 centsability4me 04/04/17 02:37:50 PM
#5671   Been accumulating for over 2 years JackAskSlap 03/29/17 09:11:05 AM
#5670   .0074 X .0088 centsability4me 03/24/17 12:34:47 PM
#5669   and news centsability4me 03/23/17 08:21:05 AM
#5668   .071 X .092 corvatsch 03/22/17 05:38:06 PM
#5667   .071 X .092 centsability4me 03/22/17 01:35:27 PM
#5666   0.0093 X 0.0125 centsability4me 03/14/17 11:31:02 AM
#5665   0,01 $$$$$... corvatsch 03/13/17 11:20:10 AM
#5664   Does anyone know what the restriction period is cantbelieveit 03/10/17 07:10:07 AM
#5663   TSOI 10-Q Filed... stervc 03/10/17 01:37:59 AM
#5662   OK !!!! corvatsch 02/16/17 05:37:30 PM
#5661   Cor, It needs more volume to narrow the spread centsability4me 02/16/17 05:27:21 PM
#5660   0,0062 ???? corvatsch 02/16/17 04:38:59 PM
#5659   good to see some volume centsability4me 02/16/17 10:33:15 AM
#5658   Someone bought a lot of 011's shurtha2000 02/16/17 10:12:04 AM
#5657   Link to new Pterostilbene study info : centsability4me 02/14/17 07:15:34 AM
#5656   $TSOI New Facebook Post on Pterostilbene inhibiting tumor cantbelieveit 02/08/17 03:10:03 PM
#5655   Only a 45M Float - can you imagine shurtha2000 02/08/17 12:09:44 PM
#5654   ***TSOI NEWS 2/6/17*** centsability4me 02/06/17 08:38:52 AM
#5653   Wow, this thing is just going up and Abbas14 02/04/17 10:43:39 AM
#5652   Another TSI Patent published corvatsch 02/03/17 07:47:17 AM
#5651   Another TSI Patent published centsability4me 02/03/17 07:23:14 AM
#5649   Bio Pharma startups centsability4me 02/01/17 08:03:40 AM
#5648   From the recent 10K filing, centsability4me 01/27/17 09:21:32 AM
#5647   we will know more centsability4me 01/24/17 01:45:26 PM
#5646   cor , nevjon 01/20/17 01:09:48 PM
#5645   0,0016- 0,0022..... corvatsch 01/20/17 11:47:17 AM